Studies in patients with breast cancer showing a link between clinical factors and over-expression of EGFR led to the successful treatment of chemotherapy-resistant breast tumors with agents that interfere with receptor tyrosine kinases. This evidence concerns the gene NTRK1 and breast cancer.